Key result
Early MRAs post-HF or MI reduce mortality ~13% and lower worsening HF despite increased hyperkalemia risk.
Why the study?
The study was conducted to evaluate the impact of MRA initiation in patients with HF within a few weeks after a decompensation event or acute myocardial infarction with cardiac dysfunction.
Does early initiation of mineralocorticoid receptor antagonists reduce all-cause death and worsening heart failure in patients recently hospitalized for heart failure decompensation or acute myocardial infarction with left ventricular dysfunction?
Does early initiation of mineralocorticoid receptor antagonists reduce all-cause death and worsening heart failure in patients recently hospitalized for heart failure decompensation or acute myocardial infarction with left ventricular dysfunction?
Early initiation of MRAs within 60 days of acute decompensated heart failure or post-AMI LV dysfunction safely improves survival and reduces worsening heart failure, despite a modest increase in hyperkalemia.
Supports early MRA initiation after decompensated HF or MI; reinforces RCT evidence for mortality and HF reduction despite hyperkalemia.
Background and aims To conduct a meta-analysis of randomized controlled trials (RCTs) to evaluate the impact of mineralocorticoid receptor antagonists (MRAs) initiation in patients with heart failure (HF) within a few weeks after a decompensation event or acute myocardial infarction with cardiac dysfunction. Methods Four electronic databases were screened for eligible studies. Randomized controlled trials were included if they assessed MRA initiation either during an index hospitalization for HF or within 60 days following a first episode of HF decompensation or acute myocardial infarction with newly documented left ventricular dysfunction (i.e. <50%). When RCTs did not fulfil the eligibility criteria, subgroup analyses were examined and included if eligible. Efficacy endpoints were all-cause death, worsening HF, and length of hospital stay. Safety endpoints included worsening renal failure, hypokalaemia, and hyperkalaemia. A pre-specified subgroup analysis for efficacy endpoints was planned by clinical setting (acute ischaemic vs non-ischaemic HF). Six RCTs with 9770 patients were included. Results Early MRA use was associated with a significantly lower risk of hypokalaemia [risk ratio (RR) 0.39, 95% confidence interval (CI) 0.26–0.58], without increasing the risk of worsening renal failure or hypotension, but with a modest increase in hyperkalaemia risk. Mineralocorticoid receptor antagonist initiation within 60 days after decompensation significantly reduced the risk of all-cause death (RR 0.87, 95% CI 0.79–0.95) and worsening HF (RR 0.81, 95% CI 0.72–0.91), with no effect on hospital length, when compared with usual care. These benefits were consistent in acute ischaemic vs non-ischaemic HF. Conclusions Early MRA initiation was associated with improved prognosis when compared with usual care, though accompanied by an increased risk of hyperkalaemia, warranting close follow-up after initiation. PROSPERO Registration number CRD42025649719
No takes yet. Share an insight, caveat, or question.
Laborante et al. (2026) studied this question. Early initiation of MRAs within 60 days post-decompensated HF or MI reduced all-cause death by 13% and worsening HF by 19%, with increased hyperkalaemia risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: